NCT04116203View on ClinicalTrials.gov

Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Polycystic Ovary SyndromeLipid Metabolism Disorders
Interventions
DRUG

Metformin

Manufacturer's standard 500 mg. Submission Control No.:128147

COMBINATION_PRODUCT

Fish Oil and Metformin

Combo of 2 other arms

DIETARY_SUPPLEMENT

Fish Oil

NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral

Trial Locations (2)

T6G 2B7

9-111 Endocrinology Department, UofA Hospital, Edmonton

T6G 2E1

2-004 Li Ka Shing Centre, UofA, Edmonton

All Listed Sponsors
collaborator

Women and Children's Health Research Institute, Canada

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Alberta Diabetes Institute

OTHER

collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

University of Alberta

OTHER

NCT04116203 - Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS) | Biotech Hunter | Biotech Hunter